Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PARG | Q86W56 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ALOX5AP | P20292 | 10/20 | 0.42 |
| ▸ | FEN1 | P39748 | 10/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2803354 | 0.91 | NSD2 (0.58) | NSD2MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL13075810 | 0.88 | NSD2 (0.51) | NSD2MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL8534729 | 0.80 | NSD2 (0.49) | NSD2MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL634084 | 0.79 | NSD2 (0.51) | NSD2MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL30565211 | 0.78 | CA1 (0.52) | NSD2MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL3404809 | 0.78 | NSD2 (0.69) | NSD2MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL2893576 | 0.78 | NSD2 (0.50) | NSD2MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL264098 | 0.78 | CA1 (0.52) | NSD2MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL1111419 | 0.78 | NSD2 (0.50) | NSD2MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL3583413 | 0.78 | NSD2 (0.50) | NSD2MAPTSMN1; SMN2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312616-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-10-05 | — | — | US | disclosed |
| US-20210139514-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312616-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | NSD2 4290/4885MAPT 4877/4885SMN1; SMN2 4797/4885 |
| US-20210139514-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | NSD2 4290/4885MAPT 4877/4885SMN1; SMN2 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.